KARACHI, July 25 — Cost-effectiveness analysis, a method of comparing the relative costs and outcomes of different courses of action, has become a standard tool in health services where assigning a monetary value to health effects may be inappropriate. The approach is expressed as a ratio: the denominator is a health gain — such as years of life, premature births averted, or sight-years gained — and the numerator is the cost.
The most common outcome measure is the quality-adjusted life year, or QALY, which combines length and quality of life into a single figure. Unlike cost–benefit analysis, which puts a dollar figure on every effect, cost-effectiveness analysis avoids monetising health directly.
The encouraging part is that this distinction allows health systems to compare interventions on medical grounds rather than purely financial ones. Patients and policymakers can see the health return for each rupee or dollar spent, without reducing a life saved to a price tag.
How CEA works
The analysis is often visualised on a four-quadrant plane, with cost on one axis and effectiveness on the other. The core calculation is the incremental cost-effectiveness ratio, or ICER, which measures the change in costs divided by the change in effects. A cheaper intervention might be chosen if its performance is only slightly inferior, while a more costly one may be selected if it provides an enormous improvement in outcome.
The goal is to maximise average health gain for available resources. Distributional cost-effectiveness analysis extends the basic model to incorporate concerns for how outcomes are spread across populations.
Early findings suggest this approach helps tackle health inequality by balancing efficiency with equity. It asks not only whether an intervention provides good value, but also whether it narrows the gap between groups.
Beyond medicine
The concept applies to many organised activities. In military acquisitions, for example, tank designs are compared on purchase price, operating radius, top speed, rate of fire, armour protection, and gun calibre and armour penetration. A cheaper tank may be selected if performance is slightly inferior; a more costly tank may be favoured when it delivers a major battlefield advantage.
The same logic — cost versus effect — underpins decisions in pharmacoeconomics, where interventions are judged against effect measures such as number of patients cured, reduction in diastolic blood pressure in millimetres of mercury, or symptom-free days. Clinicians also consider non-monetary factors — side effects, influence on other prescriptions, and minor inconveniences such as a bad aroma or taste for children.
These details are selected based on clinical judgment. The incremental cost-effectiveness ratio becomes a practical guide for vaccine adoption decisions, evaluating the cost per health gain from different immunisation strategies. Consult your doctor for medical advice.
